Clinical Trial Update: Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial of Iressa (gefitinib) for patients with EGFR mutation-negative non-small cell lung cancer; the trial status is listed as UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Nonsmall Cell Lung Cancer | Phase 2 | Status: UNKNOWN